Fo-Ti

Clinical Summary

Polygonum multiflorum (Fo-Ti / He Shou Wu) is a TCM botanical from the Polygonaceae family with a complex phytochemistry centered on stilbene glycosides (primarily 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside, TSG) and anthraquinones (emodin, physcion, rhein). Traditional use for hair darkening, cognitive support, and longevity spans centuries in East Asia. The root is the medicinal portion.

Critical distinction: Raw Fo-Ti (Sheng Shou Wu) has higher anthraquinone content and is significantly more hepatotoxic. Prepared Fo-Ti (Zhi He Shou Wu), processed via steaming with black bean liquid (traditionally 9 cycles), reduces anthraquinones by 30-60% and shifts the stilbene profile toward the safer trans-TSG isomer. Always use prepared form for supplementation.

The evidence wall: No single-ingredient human RCT exists for any Fo-Ti indication. The only two human studies (AD multi-herb N=209, dyslipidemia multi-herb N=80) both used multi-herb formulas where Fo-Ti's contribution is unattributable. The best human-relevant data for hair is ex vivo follicle studies (PMID: 28109001). Preclinical data is extensive and consistent across labs — neuroprotective, melanogenic, metabolic, and anti-aging effects are well-characterized in animal models. But animal → human translation remains unproven.

The dominant safety signal: Idiosyncratic hepatotoxicity — unpredictable, potentially fatal liver injury occurring in susceptible individuals even with processed forms. HLA-B*35:01 has been identified as a genetic susceptibility allele, with emodin-specific T-cell activation (PMID: 38969149, 2024). The TSG metabolite (deglycosylated aglycone), not TSG itself, is the primary immune-activating species (PMID: 40892063, 2025). Both raw and processed forms inhibit M2 macrophage polarization, meaning processing reduces but does not eliminate immune-mediated risk (PMID: 39999927, 2025).

Bottom line: Fascinating preclinical pharmacology, but the risk-benefit ratio for oral supplementation is unfavorable. Safer alternatives exist for every claimed indication. Revisit if topical formulations, purified TSG, or pharmacogenomic screening change the equation.

Indications & Evidence

Reading this table: Stars = evidence volume/quality. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal data or very limited human | 1/5 No evidence, theoretical, or debunked

Notes on specific indications:

• Hair pigmentation is the strongest traditional claim. Human-relevant data is limited to ex vivo follicle melanin increase (PMID: 28109001) — no human clinical trial exists. PMID 26640791 is a mouse study (C57BL/6 with H2O2-induced fade), not a human trial despite PubMed misclassification as "RCT." A novel Th22/IL-22 immune-mediated hair regeneration mechanism was identified in 2026 (PMID: 40983305). Individual response is highly variable.
• Cognitive claims were previously rated 3/5 in the original file; downgraded to 2/5 because all evidence is animal/in vitro. The only human study (PMID: 20622335, N=209) used a multi-herb formula, making Fo-Ti's contribution unattributable.
• Testosterone/libido is a marketing myth with no scientific basis. Likely confused with Tongkat Ali.
• NAFLD indication carries a WARN because many patients with metabolic syndrome have pre-existing fatty liver — a contraindication for Fo-Ti use.

Prescribing

Dosing Table

Cycling protocol (theoretical, unvalidated): 2-3 months on, 1 month off. Rationale: liver recovery. No evidence this reduces risk. Effects (hair pigmentation) may diminish during off periods.

Formulation Table

Safety

Interactions Table

Contraindications

Absolute:

• Any liver disease (hepatitis A/B/C, cirrhosis, NAFLD/NASH, fatty liver, Gilbert's syndrome, drug-induced liver injury history, baseline ALT/AST >1.5x ULN)
• Pregnancy and lactation
• Concurrent hepatotoxic medications (see Interactions)
• Active alcohol use or regular alcohol consumption
• Known hypersensitivity to Polygonaceae family
• HLA-B*35:01 carriers (if genotyped — associated with emodin-specific T-cell activation, PMID: 38969149)

Relative (extreme caution + medical supervision only):

• Polypharmacy (>5 medications)
• Age >75 with comorbidities
• Renal impairment (GFR <60 mL/min)
• Bleeding disorders or anticoagulant use
• Scheduled surgery within 2 weeks (discontinue)
• History of idiosyncratic drug reactions

Adverse Effects

Hepatotoxicity (most serious):

• Incidence: Rare but serious (~1:1,000 to 1:10,000 users; exact rate unknown)
• Severity: Ranges from asymptomatic enzyme elevation to acute liver failure requiring transplant
• Onset: Typically 1-24 weeks (median 8-12 weeks — peak risk period)
• Type: Idiosyncratic (unpredictable; not strictly dose-dependent)
• Mechanism (2024-2025 updates): TSG is biotransformed to a reactive ortho-benzoquinone intermediate that covalently modifies hepatic proteins (PMID: 40037093). The deglycosylated TSG metabolite activates immune cells (PMID: 40892063). HLA-B*35:01 predisposes to emodin-specific T-cell activation (PMID: 38969149). TNF-alpha synergizes with PM to drive hepatotoxicity via gut microbiota disruption (PMID: 41667031).
• Presentation: Asymptomatic ALT/AST elevation → jaundice → fatigue → RUQ pain → dark urine → severe: hepatic encephalopathy, coagulopathy
• Management: Immediate discontinuation; NAC may help; severe cases require transplant evaluation
• Risk factors: Raw form, duration >3 months, >15 g/day, concurrent hepatotoxins, pre-existing liver disease, HLA-B*35:01 (emerging), female sex (zebrafish data, PMID: 38518638)
• Human-specific genotoxicity signal: PM metabolites are mutagenic with human S9 activation but NOT rat S9 (PMID: 39271730) — rat safety data may underestimate human risk

Common (1-10%):

• GI upset: nausea (5-10%), diarrhea (3-8%, especially raw/anthraquinone-rich), abdominal cramping (2-5%). Management: Take with food; reduce dose; use prepared form.
• Mild rash (2-5%). Management: Discontinue; antihistamine.

Uncommon (0.1-1%): Dizziness, headache, fatigue (distinguish from liver injury).

Rare (<0.1%) but serious:

• Acute liver failure (see above)
• Stevens-Johnson syndrome (case reports)
• Renal tubular necrosis (rare case reports; causality uncertain)
• Vanishing bile duct syndrome / ductopenia (PMID: 38584108, 2024 case report)

FAERS Signal Table

Reading FAERS data: FAERS is non-informative for Fo-Ti. The well-documented hepatotoxicity comes entirely from published case series in medical literature (hundreds of cases, predominantly from China, UK, Australia), not from FAERS. This reflects FAERS limitations for supplements, not PM safety. The absence of FAERS signal does NOT indicate safety.

Monitoring Table

Discontinue immediately if: ALT/AST >3x ULN, total bilirubin >2x ULN, any symptoms (jaundice, fatigue, RUQ pain, dark urine), unexplained PT/INR prolongation.

Post-discontinuation: Continue LFTs every 2-4 weeks until normalized (may take 4-12 weeks). Permanent liver damage possible in severe cases.

Special Populations

Hepatic Impairment

Renal Impairment

Pregnancy & Lactation

• Contraindicated. No controlled studies. Anthraquinones may stimulate uterine contractions (animal data). Unknown excretion into breast milk. Infant liver immaturity increases vulnerability. Traditional Chinese medicine avoids use during pregnancy.

Synergies & Stacking

Key recommendation: Given hepatotoxicity risk, always combine Fo-Ti with milk thistle if proceeding with supplementation.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Note: HLA-B*35:01 genotyping is not yet standard clinical practice for supplement screening. This is emerging pharmacogenomic evidence. If genotype is unknown, assume standard hepatotoxicity risk and monitor accordingly.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-cautiously-positive across ~200-300 reports (Reddit, Longecity, iHerb/Amazon reviews, long hair forums, Chinese health media). Hair effects are the most consistently discussed benefit; liver anxiety dominates safety threads.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: YES — Wuxian/Infinitus (无限极), major Chinese MLM company, faced consumer liver injury lawsuits over HSW-containing products. Product contents unverifiable. SIGNIFICANT RED FLAG.
• Influencer concentration: No single Western influencer dominates, but vendor content marketing is the primary information source. Lost Empire Herbs, Dragon Herbs, and Primal Herb collectively produce the majority of English-language Fo-Ti content online while selling the product.
• Astroturfing signals: No obvious coordinated astroturfing on Reddit or Longecity. iHerb/Amazon reviews appear organic. The concern is vendor information dominance, not fake reviews.
• Commercial bias: Lost Empire Herbs publishes articles actively downplaying liver risk ("He Shou Wu Liver Damage? Review of the Evidence") while selling the product. Dragon Herbs markets Ron Teeguarden as a TCM authority figure. Both have clear conflicts of interest.
• Korean substitution scandal: In Korea, Cynanchum wilfordii (Baek Su O) was widely sold as a substitute for He Shou Wu (Ha Su O). Different species. Consumer fraud cases and regulatory action followed.
• Origin myth: The legend of "Mr. He" is repeated uncritically across virtually all vendor sites as marketing narrative.

Folk vs Clinical Reality Check

Community consensus on gray hair darkening partially aligns with preclinical evidence — tyrosinase activation, MITF upregulation, and Th22/IL-22 hair follicle stem cell activation are real mechanisms demonstrated in human tissue (ex vivo) and animal models. The high individual variance reported by users is consistent with the expected genetic/epigenetic variability in melanocyte function. However, community reports of rapid dramatic reversal (weeks) contradict the hair growth cycle timeline (months). Energy/mood improvements reported by users have no clear mechanistic explanation from the literature and may reflect placebo response or general antioxidant effects. The 30% non-responder rate aligns with the unpredictable individual variation seen in all herbal supplements.

Deep Dive: Mechanisms & Research

Key Mechanisms (Ataraxia-Vetted)

TSG (primary bioactive) — mechanisms WITH clinical translation potential:

• Nrf2/antioxidant response: Upregulates SOD, catalase, glutathione peroxidase. Reduces oxidative damage to proteins, lipids, DNA. Well-characterized across models. Translation: plausible but unproven in humans.
• NF-κB inhibition / anti-inflammatory: Suppresses TNF-α, IL-1β, IL-6. Modulates COX-2/iNOS. Translation: standard anti-inflammatory pathway shared by many polyphenols.
• BDNF upregulation + AChE inhibition: Enhances neurotrophic support and acetylcholine availability. Translation: similar to established nootropics (bacopa, huperzine A) but no human confirmation for Fo-Ti.
• Tyrosinase / MITF activation (melanogenesis): Rate-limiting for melanin synthesis. Confirmed in human hair follicles ex vivo. Translation: strongest mechanism-to-target connection; topical delivery most promising.
• Th22/IL-22 hair follicle stem cell activation (2026): Novel immune-mediated hair regeneration pathway (PMID: 40983305). Translation: early but mechanistically interesting.
• PTP1B inhibition / AMPK activation: Insulin sensitization and glucose metabolism. IC₅₀ 15-25 µM for dianthrones. Translation: plausible metabolic pathway but many compounds share this target.
• TREM2-mediated microglial Aβ clearance (2025): TSG promotes amyloid clearance via PI3K/AKT (PMID: 39948751). Translation: clinically relevant Alzheimer's pathway but animal-only data.

Preclinical-only mechanisms (no clinical translation yet):

• Sirtuin activation (SIRT1/SIRT3), autophagy enhancement, telomere protection, p53/p21 modulation — all demonstrated in cell culture and C. elegans. Requires decades of human data to validate longevity claims.
• Mitophagy via PINK1/Parkin (skin flap survival), USP10/YBX1 (stroke recovery) — novel mechanisms but animal-only.
• Ferroptosis induction in cancer cells (TNBC, colorectal, prostate, mesothelioma) — preclinical oncology; far from clinical application.

Bioactive Compounds

TSG (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside):

• Primary quality control marker (30-50% of total stilbenes). Structurally similar to Resveratrol with glucose moiety (more stable, more water-soluble). Exists as trans (bioactive) and cis isomers. Oral bioavailability estimated 15-30% (no human PK study). T½: 2-4 hours. Crosses BBB (animal PK confirmed, PMID: 40532398). Peak plasma: 1-2 hours. Metabolized by gut bacteria (deglycosylation) and liver (glucuronidation, sulfation). The deglycosylated metabolite is the primary hepatotoxic species (PMID: 40892063) and is further biotransformed to reactive ortho-benzoquinone (PMID: 40037093).

Anthraquinones (emodin, physcion, rhein, aloe-emodin, chrysophanol):

• Secondary metabolites. Laxative effect. Associated with hepatotoxicity. Poor oral bioavailability (1-5% for free forms). Processing converts free → bound glycosides (reduced bioavailability = safety benefit). Emodin activates HLA-B*35:01-restricted T cells (PMID: 38969149). Paradoxically, emodin and physcion from processed PM activate FXR and are hepatoprotective in cholestasis models (PMID: 41487497). Trans-emodin dianthrones are newly identified hepatotoxins more toxic than free anthraquinones (PMID: 40319934).

Other constituents: Phospholipids (lecithin, cephalin — neuroprotective support), tannins (10-20% — bind iron), flavonoids (quercetin, kaempferol), polysaccharides (immunomodulatory, lifespan extension in C. elegans).

Processing: Raw vs Prepared

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Critical gap: ZERO registered human RCTs of Polygonum multiflorum as a single-ingredient intervention. All trials use multi-herb TCM formulas where PM is one component among many. As of July 2024, ChiCTR (China Clinical Trial Registry) no longer accepts TCM trials — these are redirected to ITMCTR.

Regulatory Status

• FDA (US): Available as dietary supplement; not FDA-approved as drug. No specific warning letter identified. LiverTox database entry documents PM as established cause of herb-induced liver injury (PMID: 31644102).
• MHRA (UK): Formal safety warning issued 2006 after 7 Yellow Card reports of liver disorders (jaundice, hepatitis). Affected products: Shen Min, Shou Wu Wan.
• TGA (Australia): Permitted in listed medicines. Mandatory label warning: "Warning: Fallopia multiflora may harm the liver in some people." SuperFeast He Shou Wu cancelled from ARTG for unacceptable quality/safety/efficacy.
• EMA (EU): No specific EMA monograph. Individual member states may restrict.
• NMPA/Chinese Pharmacopoeia (China): Listed (both raw and processed forms). PM is the most commonly reported cause of herbal product-related liver injury in China. Chinese guideline T/CACM 1328-2019 provides specific usage parameters (PMID: 32237468).
• Regulatory context: PM is not "unapproved because it's commercially unviable" — it's a widely sold supplement. The safety warnings are driven by genuine, well-documented hepatotoxicity, not by pharma competition or regulatory inertia.

Ataraxia Verdict (as of 2026-04-15)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to Tradition (HIGH): "Used for centuries in TCM" is the foundational claim. Longevity of use does not establish efficacy — TCM also employed mercury compounds and aristolochic acid herbs, both now recognized as dangerous.
• Hasty Generalization (HIGH): Animal model results are presented with confidence that exceeds the evidence. No single-ingredient human RCT exists. Animal → human translation rate for CNS compounds is ~8%.
• Appeal to Nature (MEDIUM): "Natural herb" framing implies safety. Some of the most potent toxins known are natural.
• Cherry-picking (MEDIUM): Published literature and vendor content disproportionately cite positive preclinical results. Negative/null studies are underrepresented. The file's original 3/5 rating for cognition was inflated.

Evidence Gaps

• No human pharmacokinetic studies for TSG or whole extract
• No validated pre-supplementation biomarkers to predict hepatotoxicity (ML metabolomic approach emerging, PMID: 41933744)
• No human RCT of PM as single ingredient for ANY indication
• No head-to-head comparisons with alternatives (Bacopa for cognition, minoxidil for hair, Resveratrol for anti-aging, Berberine for metabolic)
• No long-term safety data >6 months in controlled settings
• No dose-response studies in humans
• No human gut microbiome interaction data
• Sex-specific toxicity data limited to zebrafish (PMID: 38518638)
• HLA-B*35:01 prevalence in target populations not characterized

Bias Flags (Mode 4: First Principles)

• "Traditional use = evidence" (Load-bearing: HIGH). Centuries of use documents population tolerability (survivorship bias) but does not establish efficacy for specific indications.
• "Processing makes it safe enough" (Load-bearing: HIGH). 2025 data shows both raw and processed PM suppress M2 macrophage polarization. Processing reduces but does not eliminate immune-mediated risk.
• "Animal cognitive benefits will translate" (Load-bearing: HIGH). CNS drug translation rate from animals is ~8%. Many promising animal nootropics failed in humans.
• "Fo-Ti is irreplaceable" (Load-bearing: LOW). Safer alternatives exist for every claimed indication.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Lost Empire Herbs dominates English-language search results, publishes articles downplaying liver risk while selling the product. Dragon Herbs positions Ron Teeguarden as a TCM authority. Primal Herb produces affiliate-oriented content with inflated claims ("15 benefits").
• Influencer economics: No single influencer dominates Western HSW promotion. Vendor content marketing is the primary information ecosystem — Lost Empire Herbs, Dragon Herbs, and Primal Herb collectively produce most accessible English-language Fo-Ti information.
• Counter-narrative manipulation: Wuxian/Infinitus (Chinese MLM) liver injury lawsuits. Product contents unverifiable.
• Cui bono summary: Pro-supplement: TCM practitioners (livelihood), supplement companies (revenue), "traditional medicine" advocates (ideological). Anti-supplement: emergency physicians (see real liver cases — HIGH credibility), regulatory bodies (enforcement mandate). Safety narrative driven by genuine clinical concern, not pharma competition.
• Red team highlight: REVERSIBILITY — liver damage may be irreversible (transplant/death cases documented), while all claimed benefits are temporary and reverse upon discontinuation. This asymmetric risk profile is the single most damning angle.

Decision Support (Mode 3: Clarity Compass)

• General health utility: 3/10 — interesting preclinical mechanisms, but no proven human benefit with genuine risk of serious irreversible harm
• Opportunity cost: $540-1920/year including mandatory LFT monitoring; complexity cost of cycling and monitoring; safer alternatives available for every indication
• Verdict: SKIP
• Conditions for revisiting: (a) Purified TSG products with validated human safety data become available; (b) Topical formulations for hair that bypass systemic exposure are developed and tested; (c) Pharmacogenomic screening (HLA-B*35:01) enables individual risk stratification before supplementation

Bottom Line

Fo-Ti has some of the most consistent preclinical pharmacology in the botanical supplement space — neuroprotective, melanogenic, metabolic, and anti-aging effects replicated across dozens of labs and models. But the evidence wall between "works in animals" and "works in humans" has not been breached for a single indication. Zero single-ingredient human RCTs exist. Meanwhile, the hepatotoxicity risk is real, mechanistically characterized (HLA-B*35:01, TSG reactive metabolite, immune activation), and potentially irreversible — including documented fatalities. For a healthy person exploring self-experimentation, the math doesn't work: you're gambling your liver on unproven benefits that have safer alternatives. The most promising future direction is topical TSG for hair (bypasses liver) or pharmacogenomic pre-screening (identifies who should never take it). Until one of these changes the equation, skip oral Fo-Ti.

Practical Notes

Brands & Product Selection

Reputable sources (not endorsements):

1. Dragon Herbs (Ron Teeguarden) — transparent sourcing, traditional preparation, COA available
2. Plum Flower — TCM herbs with batch testing
3. Mayway — supplies TCM practitioners, rigorous testing
4. Jing Herbs — prepared extracts, COA available

Quality markers:

• "Prepared" or "Zhi He Shou Wu" explicitly stated
• TSG ≥1.0% (Chinese Pharmacopoeia standard)
• Emodin <0.10%
• COA available on request (heavy metals: Pb <2 ppm, As <0.5 ppm, Cd <0.5 ppm, Hg <0.1 ppm)
• Third-party tested (USP, NSF, ConsumerLab)

Red flags: No "prepared/processed" mention (assume raw); "FDA approved" claims (false); "cure gray hair" claims; no COA; <$10/month (quality concerns); proprietary blends; no batch/lot number.

Storage & Handling

• Temperature: 15-25°C. Light: protect from UV (stilbenes are light-sensitive; amber glass or opaque container). Humidity: keep dry; desiccant packets in humid environments. Shelf life: dried root 2-3 years; extracts 18-24 months; use within 12 months after opening. Degradation signs: excessive darkening, musty odor, clumping.

Palatability & Compliance

• Prepared root: slightly bitter, earthy, astringent. Capsules eliminate taste issue. Traditional decoction: strong bitter taste; mask with honey, citrus, or licorice root. Powder: bitter, difficult to mask — berry smoothies work best. Capsules/standardized extracts are the practical choice for compliance.

Cost

Hidden cost: LFT monitoring — $50-150 per panel x 6-8 times in first year = $300-1200. This is a mandatory cost for responsible Fo-Ti use, not optional.

What We Don't Know

• Who gets liver damage. HLA-B*35:01 is a start, but doesn't explain all cases. No pre-supplementation screening test exists. You cannot predict your individual risk.
• Whether it actually works in humans for anything. Zero single-ingredient human RCTs. All claimed benefits are extrapolated from animals, cell culture, or multi-herb formulas.
• Human pharmacokinetics. No published human PK study for TSG. Bioavailability, optimal dosing, and inter-individual variability remain unknown.
• Long-term safety. No controlled data beyond 6 months. Cumulative risk not quantified. Cycling protocols are unvalidated folk practice.
• Dose-response in humans. Not established for any indication. "More" may not mean "better" — and may mean "more hepatotoxic."
• Whether topical delivery works for hair. Most promising safety-bypassing approach, but no human clinical trial of topical TSG/Fo-Ti for gray hair reversal.
• Whether processed form is meaningfully safer. Processing reduces anthraquinones and dianthrones, but both raw and processed forms suppress M2 macrophage polarization. The immune-mediated mechanism may not be fully addressed by processing.
• Sex-specific risk. Female zebrafish show greater susceptibility; MHRA UK cases were mostly women. No human pharmacokinetic sex-stratification data.
• Gut microbiome role. TSG is metabolized by gut bacteria; individual microbiome composition may determine both efficacy and toxicity. Completely uncharacterized in humans.
• Whether PM metabolites are mutagenic in humans at supplemental doses. Human S9 activation produces mutagenic metabolites in Ames test (PMID: 39271730), but in vivo relevance at typical doses is unknown.

References

Systematic Reviews & Safety (most authoritative)

1. Liu Y, Wang W, Sun M, et al. (2019). PM-induced liver injury: clinical characteristics, risk factors, material basis, action mechanism. Front Pharmacol 10:1467. PMID: 31920657 — Comprehensive hepatotoxicity review; idiosyncratic immune-mediated mechanism.
2. Teka T, Wang L, Gao J, et al. (2021). PM: newly isolated compounds, potential hepatotoxic compounds and mechanisms. J Ethnopharmacol 271:113864. PMID: 33485980 — Anthraquinones and cis-TSG as hepatotoxins.
3. Meng YK, Li CY, Li RY, et al. (2017). Cis-stilbene glucoside induces immunological idiosyncratic hepatotoxicity via PPAR-γ suppression. Acta Pharmacol Sin 38(10):1340-1352. PMID: 28649126 — Cis-isomer as key hepatotoxin.
4. Liu Y, Wang Q, Yang J, et al. (2018). PM: chemical analysis, processing mechanism, quality evaluation, hepatotoxicity. Front Pharmacol 9:364. PMID: 29713283 — Processing reduces anthraquinones 30-60%.
5. Lin L, Ni B, Lin H, et al. (2015). Traditional usages, botany, phytochemistry, pharmacology and toxicology. J Ethnopharmacol 159:158-83. PMID: 25449462 — Comprehensive ethnopharmacological review.
6. Bounda GA, Feng YU. (2015). Review of clinical studies of PM and isolated bioactive compounds. Pharmacognosy Res 7(3):225-36. PMID: 26130933 — Notes lack of high-quality human RCTs.
7. Wang C, Dai S, Gong L, et al. (2022). Pharmacology, toxicity and PK of TSG. Front Pharmacol 12:791214. PMID: 35069206 — TSG-focused review; no human PK studies.
8. Zhu C, Li J, Tang W, et al. (2025). TSG from PM: systematic review on anti-aging. Int J Mol Sci 26(7):3381. PMID: 40244282 — Sirtuin, mitochondrial, autophagy mechanisms; no human longevity data.
9. Qian L, et al. (2024). Comprehensive review: phytochemistry, pharmacology, toxicology, detoxification. Front Pharmacol. PMID: 38953108.
10. Byeon JH, et al. (2019). Systematic review of herb-induced liver injury. J Ethnopharmacol. PMID: 30639232 — PM prominently featured.
11. Xiao XH, Wang JB, et al. (2024). Guidelines for safe use of Polygoni Multiflori Radix (T/CACM 1328-2019). Acupunct Herb Med 4(2):151-158. PMID: 32237468 — Chinese guideline: biomarkers of susceptible populations.

Hepatotoxicity Mechanism (2024-2026 updates)

12. Gao Y, et al. (2024). HLA-B*35:01-mediated activation of emodin-specific T cells. J Ethnopharmacol. PMID: 38969149 — First pharmacogenomic risk allele for PM-DILI.
13. Wang X, et al. (2025). Deglycosylated TSG metabolite contributes to immune-mediated hepatotoxicity. Arch Toxicol. PMID: 40892063 — TSG aglycone is the immune-activating species.
14. Li M, et al. (2025). Two-step metabolic activation of TSG to reactive ortho-benzoquinone. Drug Metab Dispos. PMID: 40037093 — Maps reactive metabolite formation.
15. Zhang Y, et al. (2025). Common immunotoxicity of raw and processed PM: M2 macrophage polarization inhibition. Toxicon. PMID: 39999927 — Processing reduces but doesn't eliminate immune risk.
16. Chen L, et al. (2026). TNF-alpha synergy with PM-induced idiosyncratic liver injury. Chem Biol Interact. PMID: 41667031 — TNF-alpha as susceptibility co-factor.
17. Liu J, et al. (2026). Biomarkers for PM-induced liver injury: ML metabolomics + transcriptomics. J Ethnopharmacol. PMID: 41933744 — First human-cohort biomarker study.
18. Park S, et al. (2024). Differential genotoxicity of PM in rat and human S9. Sci Rep. PMID: 39271730 — Human-specific mutagenicity signal.
19. Wang H, et al. (2024). Emodin-8-O-glucopyranoside hepatotoxicity and gender differences in zebrafish. Phytomedicine. PMID: 38518638 — Female zebrafish more susceptible.
20. Li Y, et al. (2025). Hepatotoxicity of trans-emodin dianthrones. J Ethnopharmacol. PMID: 40319934 — Dianthrones more toxic than free anthraquinones.
21. Zhou Q, et al. (2025). Processing-induced reduction in dianthrones content. Animal Model Exp Med. PMID: 39439047 — Processing reduces dianthrones >90%.
22. Xu F, et al. (2024). Vanishing bile duct syndrome from PM [case report]. PMID: 38584108.
23. Chen W, et al. (2025). Clinical characteristics of PM-induced liver injury vs other DILI. PMID: 40528591.

Neuroprotection & Cognition

24. Hou Y, Yang Q, Zhou L, et al. (2011). TSG improves learning and memory in aged rats. Can J Physiol Pharmacol 89(11):801-9. PMID: 22032649 — Morris water maze +25-35%.
25. Wang R, Tang Y, Feng B, et al. (2007). TSG effects on hippocampal synapses in aged rats. Neuroscience 149(4):739-46. PMID: 17935895 — Synapse density improvement.
26. Yu F, Xue W, Dong L, et al. (2019). TSG suppresses NADPH oxidative stress in cerebral ischemia. ECAM 2019:3913981. PMID: 31379960 — Infarct reduction 30-45%.
27. Gao D, Chen C, Huang R, et al. (2021). TSG in APP/PS1 transgenic mice. Curr Med Sci 41(2):279-286. PMID: 33877543 — Aβ plaques reduced 30-40%.
28. Chen L, Huang J, Xue L. (2010). Compound PM extract on Alzheimer's disease. PMID: 20622335 — N=209 multi-herb; modest improvement.
29. Liu JJ, et al. (2025). Ginseng + PM formula protects brain in AD. Front Pharmacol 16:1461177. PMID: 40051562 — Synergistic neuroprotection.
30. Kim S, et al. (2025). PM improves PM2.5-induced neuroinflammation. Int J Mol Sci. PMID: 41516109 — Korean study.
31. Zhang L, et al. (2026). TSG protective effect on MPTP Parkinson's mice. Histol Histopathol. PMID: 40740145 — Gut-brain axis mechanism.
32. Li X, et al. (2025). TSG counteracts microglial glycolytic reprogramming and necroptosis. Sci Rep. PMID: 40596006.
33. Wang Y, et al. (2025). TSG reduces Aβ via TREM2/PI3K/AKT in APP/PS1 mice. Basic Clin Pharmacol Toxicol. PMID: 39948751.
34. Chen H, et al. (2024). TSG promotes mitophagy via USP10/YBX1 after cerebral ischemia. eNeuro. PMID: 39406480.
35. Liu Y, et al. (2024). TSG alleviates cerebral ischemia via GluN2B-CaMKII-ERK1/2. Phytomedicine. PMID: 38677275.
36. Park J, et al. (2024). Preclinical evidence of PM against cognitive impairment/AD [Korean review]. J Pharmacopuncture. PMID: 38948308.

Hair & Dermatology

37. Han MN, Lu JM, Zhang GY, et al. (2015). PM for hair graying: mechanistic studies. Biomed Res Int 2015:651048. PMID: 26640791 — Mouse study (C57BL/6, H2O2-induced fade); MC1R/α-MSH/tyrosinase activation. PubMed misclassified as "RCT" but abstract is animal-only.
38. Sextius P, Betts R, et al. (2017). PM protects melanocytes, potentiates follicle pigmentation ex vivo. Int J Cosmet Sci 39(4):419-425. PMID: 28109001 — Melanin +25-40% in human follicles.
39. Shin JY, Choi YH, et al. (2020). PM extract supports hair growth by elongating anagen and abrogating androgen effect. BMC Complement Med Ther 20(1):144. PMID: 32398000.
40. Park HJ, Zhang N, Park DK. (2011). Topical PM induces hair growth via Shh and β-catenin. J Ethnopharmacol 135(2):369-75. PMID: 21419834.
41. Wang Z, et al. (2026). TSG promotes hair regeneration by inducing Th22 cell differentiation. J Ethnopharmacol. PMID: 40983305 — Novel immune-mediated mechanism.
42. Lee K, et al. (2025). Rhynchosia nulubilis + PM synergy on dermal papilla cells [Korean]. PLoS One. PMID: 40424268.

Metabolic & Bone

43. Ham JR, et al. (2019). PM attenuates bone loss in diabetic mice. Prev Nutr Food Sci 24(2):121-127. PMID: 31328115 — Glucose -25%.
44. Tang W, Li S, et al. (2017). Anti-diabetic activities of cis- and trans-TSG. Mol Nutr Food Res 61(8). PMID: 28054445.
45. Yang JB, et al. (2023). Dianthrone PTP1B inhibitors from PM. Bioorg Chem 135:106491. PMID: 37011521 — IC₅₀ 15-25 µM.
46. Hu M, Zeng W, Tomlinson B. (2014). Multi-herb formula for dyslipidemia [RCT]. ECAM 2014:365742. PMID: 24834096 — N=80; PM contribution unclear.
47. Chen Y, et al. (2025). TSG attenuates NAFLD via RUNX1/FGF21. Acta Pharmacol Sin. PMID: 40307458.
48. Li J, et al. (2025). TSG alleviates osteoporosis via AMPK/mTOR/ULK1. Toxicol Appl Pharmacol. PMID: 40961988.
49. Kim H, et al. (2024). PM extract alleviates glucocorticoid-induced osteoporosis. J Med Food. PMID: 38442325.

Anti-Aging & Longevity

50. Fan J, et al. (2024). PM polysaccharides extend C. elegans lifespan via DAF-16. Int J Biol Macromol 257:128724. PMID: 38103673 — +10-20%.
51. Fan J, et al. (2025). PM polysaccharides: anti-aging via p53/p21 and amino acid metabolism. Int J Biol Macromol 306:141573. PMID: 40023426.
52. Li YH, et al. (2016). TSG anti-aging advances [Chinese]. Zhongguo Zhong Yao Za Zhi 41(2):182-185. PMID: 28861960.
53. Zhang W, et al. (2024). TSG extends C. elegans longevity via DAF-16/SKN-1/SIR-2.1 mitochondrial QC. Antioxidants. PMID: 39334745.

Other Domains

54. Wang X, et al. (2025). PM stilbene glycoside oligomers induce ferroptosis in TNBC. BMC Cancer. PMID: 40229746.
55. Lee S, et al. (2024). PM suppresses lethal prostate cancer via CDC25B-CDK1. Bioorg Chem. PMID: 39180863.
56. Chen L, et al. (2026). PM in premature ovarian insufficiency [network pharmacology]. J Sci Food Agric. PMID: 41808278.
57. Li M, et al. (2024). PM extracellular vesicle-like nanovesicles for skin photoaging. Biomater Res. PMID: 39703536.
58. Zhang Y, et al. (2025). TSG PK, tissue distribution, metabolism in ischemic stroke rat. J Pharm Biomed Anal. PMID: 40532398 — Brain penetration confirmed.

Regulatory & Safety Resources

59. NIDDK LiverTox Database: Polygonum multiflorum entry. PMID: 31644102.
60. Chinese Pharmacopoeia Commission: Quality standards for processed Fo-Ti (TSG ≥1.0%, emodin <0.10%).